NDAORALTABLETPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEPMETKO (tepotinib hydrochloride) is an oral small-molecule kinase inhibitor approved in February 2021 for the treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. The drug targets MET receptor tyrosine kinase to inhibit aberrant signaling in this genetically defined patient population.
$22MPart D
Peak3.6 years to LOEAt peak commercial stage with modest Part D spending ($22M) and limited claim volume (1,056 in 2023), suggesting a niche indication with room for patient identification and awareness initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on TEPMETKO at EMD Serono Research & Development Institute, Inc.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.